Outcomes and Healthcare Resource Utilization in Patients with COVID-19 Treated with Nirmatrelvir–Ritonavir: Real-World Data Analysis

Clara Weil, Lilac Tene, Gabriel Chodick, Noga Fallach, Wajeeha Ansari, Tal Distelman-Menachem, Yasmin Maor*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Nirmatrelvir–ritonavir was granted emergency use authorization in Israel in January 2022 to treat high-risk patients with mild-to-moderate COVID-19. The aim of the study was to assess the association between nirmatrelvir–ritonavir treatment and COVID-19-related hospitalization and healthcare resource utilization (HCRU) in a country with a high level of vaccinations compared to patients who were offered treatment and declined. Methods: The Maccabi Healthcare Services dataset was used to identify high-risk SARS-CoV-2-positive adults from January to February 2022 who received nirmatrelvir–ritonavir within 5 days of symptom onset (treatment group) or who were offered nirmatrelvir–ritonavir treatment and declined it (reference group). COVID-19-related hospitalizations and all-cause mortality and HCRU within 30 days were compared between treatment and reference groups using inverse probability of treatment weighting. Results: Treatment and reference groups included 3460 (median age, 68.4 years) and 1654 (70.2 years) patients, respectively. Patients with ≥1 dose of COVID-19 vaccine accounted for 89.5% (treatment group) and 72.1% (reference group) of the total. Treatment was associated with a lower risk of COVID-19-related hospitalization (adjusted OR, 0.59 [95% CI, 0.41,0.83]). Results were similar by age group (18–64/≥65 years) and among patients with/without vaccination in the prior 180 days. There were 11 (0.3%) versus 11 (0.7%) deaths in the treatment and reference groups, respectively. Treated patients had lower inpatient HCRU and greater less intensive outpatient HCRU (e.g., telemedicine and emergency room visits). Conclusions: Nirmatrelvir–ritonavir treatment was associated with a reduced risk of COVID-19-related hospitalization and a shift to less intensive outpatient HCRU. Comparison with a reference group of nirmatrelvir–ritonavir-eligible patients who declined treatment enabled an unbiased outcome assessment. Real-world data gathered during the Omicron BA.1 variant wave of COVID-19 in Israel support the continued use of nirmatrelvir–ritonavir for high-risk adults of all ages, regardless of previous vaccinations.

Original languageEnglish
Article number6091
JournalJournal of Clinical Medicine
Volume13
Issue number20
DOIs
StatePublished - Oct 2024

Funding

FundersFunder number
Maccabbi Healthcare Services
Pfizer

    Keywords

    • healthcare resource utilization
    • hospitalization
    • nirmatrelvir–ritonavir
    • outcomes
    • SARS-CoV-2
    • treatment

    Fingerprint

    Dive into the research topics of 'Outcomes and Healthcare Resource Utilization in Patients with COVID-19 Treated with Nirmatrelvir–Ritonavir: Real-World Data Analysis'. Together they form a unique fingerprint.

    Cite this